CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2017 Gastrointestinal Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Talamonti on Surgical Advancements in Pancreatic Cancer
Dr. Mariette on a Study of Postoperative Mortality After Esophageal and Gastric Cancer Surgery
Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer
Oncology Conference Articles
Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer
Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.
In MPC, Gemcitabine/Nab-Paclitaxel More Cost Effective Than With FOLFIRINOX
Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Nivolumab With Nab-paclitaxel, Gemcitabine Shows Promise in Pancreatic Cancer
The combination regimen of the PD-1 inhibitor nivolumab (Opdivo) plus nab-paclitaxel and gemcitabine was found to demonstrate encouraging clinical activity and low toxicity levels in patients with metastatic pancreatic cancer.
Induction Regimen Achieves 80% DCR in Advanced Pancreatic Cancer
The combination of nanoparticle albumin-bound-paclitaxel and gemcitabine led to no new or unexpected adverse events in a small study of patients with locally advanced pancreatic cancer.
Analysis Confirms Survival Benefit With Nanoliposomal Irinotecan Regimen in Pancreatic Cancer
Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.
Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC
Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.
Little Correlation Between Phase II, III Trials in Advanced Pancreatic Cancer
Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.
Napabucasin Linked With Objective Responses in Advanced CRC
As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.
PD-1 Inhibitor Active in Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.
Vemurafenib Adds to PFS in BRAF-mutant mCRC
Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with
-mutant metastatic colorectal cancer.
Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC
The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.
Trend Toward Better PFS With Four-Drug CRC Regimen
Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.
Cabozantinib Active in Neuroendocrine Tumors
In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age
Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.
Progression Type in HCC Influences Survival Duration
Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.
Trastuzumab Beyond Progression Shows Promise in HER2+ Gastric Cancers
Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.
Surgical Palliation Enables Solid Food Intake in Advanced Incurable Gastric Cancer
Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.
Pembrolizumab/Ramucirumab Combo Active in Gastric Cancers
A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.
Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer
Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.
PET-Guided Treatment Improves Outcomes in Esophageal Cancer
Switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy improved pathologic complete response rates in patients with esophageal and gastroesophageal junction cancers.
Watch-and-Wait Approach a Potential Option for Patients With Rectal Cancer
A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.
Analysis Shows Link Between Daily Physical Activity and Improved mCRC Outcomes
Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.
FDA Approval in Myeloma, Priority Review in ALL, and 2017 GU Cancers Symposium Highlights
Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy
Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma
Prophylactic Letermovir Limits CMV Infections Post-Transplantation
Expert Discusses Benefit of IMRT in Gynecologic Cancers
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.